Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy
Sponsor: Columbia University
Summary
Hypoglossal nerve stimulation (HGNS) is an implantable therapy that treats obstructive sleep apnea. The study will evaluate the effect of this treatment on cardiovascular and metabolism-related measures to see if it affects patients' risk of medical problems associated with obstructive sleep apnea (OSA).
Official title: Cardiometabolic Risk Effects of Short-term Cessation of Effective Neurostimulation Therapy in OSA
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-01-05
Completion Date
2028-01
Last Updated
2025-07-10
Healthy Volunteers
No
Interventions
No HGNS therapy (HGNS-off)
Prior to enrollment in this study, participants will have been utilizing HGNS at a therapeutic voltage setting confirmed via overnight sleep study. As part of the trial, they will undergo a study arm that involves turning off HGNS therapy (HGNS-off) for between 2-4 weeks.
Locations (1)
Columbia University Medical Center
New York, New York, United States